granulomatosis

It was granted the same status by the US FDA for the treatment of Eosinophilic Granulomatosis with Polyangiitis.

The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G.

In November 2018, the FDA granted ODD for Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) and also granted ODD for the treatment of hypereosinophilic syndrome (HES) in February 2019.

(NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE[TM] (rituximab-pvvr), a biosimilar to Rituxan[R] (rituximab), for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Food and Drug Administration (FDA) has accepted the company's supplemental Biologies License Application (sBLA) and granted Priority Review for the use of Rituxan[R] (rituximab), in combination with glucocorticoids (GCC), for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age and older.

Bronchocentric granulomatosis (BG), which was first described by Liebow in 1973 (1), is a destructive granulomatous lesion, which forms in response to airway damage to the bronchi and bronchioles.

Granulomatosis with polyangiitis (GPA) (formerly named Wegener's granulomatosis) is an uncommon kind of systemic vasculitis involving small-to-medium sized vessels, and categorized as ANCA-associated vasculitities with the presence of anti-neutrophil cytoplasm antibodies (1).

"We look forward to continuing to leverage our experience and expertise in biotechnology to bring more biosimilars to patients." ABP 798 is being developed as a biosimilar candidate to rituximab, a CD20-directed cytolytic antibody that is approved in many regions for the treatment of adult patients with moderate-to-severe rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Wegener granulomatosis (granulomatosis with polyangiitis)

The liver lesion leading to hypercalcemia described in the literature is hepatic granulomatosis in chronic dialysis patient, [2] and pyogenic liver abscess as a cause of hypercalcemia has not been reported.